What Wedbush Sees Coming in ASCO’s 2020 Annual Meeting
Wedbush took a closer look at some of the companies in its coverage universe that are set to present at ASCO and what the impact may be going forward.
All Work
Chris Lange
Why Solid Growth Isn’t Propping Up Applied Materials Stock
Applied Materials shares retreated early Friday after it reported disappointing second-quarter results and offered no guidance.
Amazon Stock Is Making the Case for Death Star Status
Amazon has earned its reputation as the "Death Star" but Jeff Bezos wants to sound less like Darth Vader.
Why Growth, Not Value, Is Driving Beyond Meat Stock
Beyond Meat looks like the real deal to growth investors as the coronavirus changes consumer habits and China market beckons.
Will This COVID-19 Treatment for Cancer Patients Be a Big Hit?
AIM ImmunoTech shares ticked higher on Thursday after the company announced some big developments with the FDA concerning its treatment for cancer patients with COVID-19.
Why This FDA Update Is Huge for Applied DNA Sciences
Applied DNA Sciences shares made an incredible gain on Thursday after the company announced it had received an update from the FDA concerning its COVID-19 assay kit.
Cisco Comes Out on Top in Q3 Report
Networking giant Cisco reported third fiscal quarter earnings of $0.79 per share and $11.98 billion in revenue compared with consensus estimates that called for $0.71 in per-share earings and $11.88 billion in revenue.
Huge Sales Growth Brightens Future for Amarin Stock
There are still a lot of questions for Amarin must figure out before it gets back on track. For investors, the question is whether it is the market recovery that is lifting the stock…
The Services Business Is Making Apple Stock a Safe Bet
Slumping iPhone sales and other near-term problems are being offset by Apple's incredible services business. If anything, this makes Apple quite a safe bet.
Will Cisco Systems Outperform Again in Q3?
Cisco Systems is scheduled to release its fiscal third-quarter financial results after the markets close on Wednesday. Will it beat low expectations?
Why Juul’s European Departure Helps Altria Stock
COVID-19 has already beaten up tobacco giant Altria but things may be getting even worse as Juul, in which it has a stake, is facing fresh problems.
Why This Funding Is Crucial for Novavax
Novavax shares jumped on Tuesday after the company announced that it would be receiving a sizable investment to further produce its COVID-19 vaccine.
What’s Next for CymaBay’s NASH Study
CymaBay Therapeutics shares more than doubled on Tuesday after the company announced its first-quarter results, along with a corporate update.
Cannabis Stocks See Rising Tide in Short Interest
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected marijuana stocks increased.
Short Sellers Raise the Stakes in Major Biotechs
The April 30 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Is Semiconductor Short Interest Signaling an Overall Recovery?
The April 30 short interest data have been compared with the previous report. Short interest in most of these selected semiconductor stocks decreased.
Why a Phased Restart Is Crucial to Ford Stock
This Detroit automaker needs to get back on track, and the only way they can do that is by restarting production in a safe but effective way before it falls to penny stock status.
Second Wave of Coronavirus Cases Has Investors Rethinking Cruise Ship Stocks
Across the board, cruise companies were tossed around on Monday amid concerns that a potential second wave of coronavirus infections could stifle business.
COVID-19 Testing Continues to Lift Aytu BioScience Stock
This specialty pharmaceutical company is making good progress on multiple fronts, including changes to its board of directors and with its test for and treatment of COVID-19.
Why MyoKardia’s Late-Stage Hypertophric Cardiomyopathy Study Is a Big Hit
MyoKardia shares made an incredible gain on Monday after the company announced positive results from its late-stage pivotal clinical trial of mavacamten.